Corbus bets on cystic-fibrosis market with Resunab

http://www.mmm-online.com/pipeline/corbus-bets-on-cystic-fibrosis-market-with-resunab/article/485565/

While CFTR modulators have stolen the cystic fibrosis treatment spotlight, Corbus Pharmaceuticals has quietly tackled CF’s inflammatory and fibrotic components. Resunab, Corbus’s investigative agent, has the potential to Continue reading Corbus bets on cystic-fibrosis market with Resunab

Researchers Further Illuminate Pathway for Treatment of Cystic Fibrosis

http://www.newswise.com/articles/researchers-further-illuminate-pathway-for-treatment-of-cystic-fibrosis

CHAPEL HILL, NC – It is well established that people with cystic fibrosis (CF) have two faulty copies of the CFTR gene, but debate continues on the question of whether certain symptoms of the Continue reading Researchers Further Illuminate Pathway for Treatment of Cystic Fibrosis